**RATIONALE**

- Approximately 50,000 women in the U.S. are diagnosed with ductal carcinoma *in situ* (DCIS) each year
- Without treatment, approximately 20-30% of DCIS will lead to invasive breast cancer (1)
- However, over 97% of women are currently treated with guideline-concordant care (GCC) including surgery and/or radiation (2)
- An alternative to GCC for low-risk DCIS is active surveillance (AS) which focuses on early detection of invasion should it occur, rather than “treatment” of DCIS
- The COMET study will compare risks and benefits of AS versus GCC in the setting of a Phase III pragmatic

**OBJECTIVE**

- Primary objective: assess whether the 2-, 5-, and 7-year ipsilateral invasive breast cancer rate for AS is non-inferior to that for GCC
- Patient reported outcomes (PROs) will enable comparison of health-related quality of life and psychosocial outcomes between GCC and AS groups at baseline, 6-months and years 1-5
COMET Study (AFT-25)
Comparison of Operative to Monitoring and Endocrine Therapy for Low-risk DCIS
Lynch T, Frank L, Collyar D, Basila D, Pinto D, Partridge A, Thompson A, Hwang S.
**COMET Study (AFT-25)**  
Comparison of Operative to Monitoring and Endocrine Therapy for Low-risk DCIS

Lynch T, Frank L, Collyar D, Basila D, Pinto D, Partridge A, Thompson A, Hwang S.

<table>
<thead>
<tr>
<th>Clinical Outcomes</th>
<th>PRO: QOL and Psychosocial Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Primary endpoint:</strong> 2-year ipsilateral invasive cancer rate</td>
<td></td>
</tr>
<tr>
<td><strong>Secondary endpoints:</strong></td>
<td></td>
</tr>
<tr>
<td>• 2-year mastectomy/breast conservation rate</td>
<td>Secondary endpoints: (baseline, 6 months, years 1-5)</td>
</tr>
<tr>
<td>• 2-year contralateral invasive cancer rate</td>
<td>• Health-related QOL</td>
</tr>
<tr>
<td>• 2-year overall/disease-specific survival</td>
<td>• Anxiety and depression</td>
</tr>
<tr>
<td><strong>Other endpoints:</strong></td>
<td></td>
</tr>
<tr>
<td>• 2-year breast MRI rate</td>
<td>Exploratory endpoints:</td>
</tr>
<tr>
<td>• 2-year breast biopsy rate</td>
<td>• Symptoms, pain (baseline, 6 months, years 1-5)</td>
</tr>
<tr>
<td>• 2-year radiation rate</td>
<td>• Body image, sexual function (baseline, 6 months, years 1-5)</td>
</tr>
<tr>
<td>• 2-year chemotherapy rate</td>
<td>• Quality of decision-making (baseline, 2-years)</td>
</tr>
<tr>
<td></td>
<td>• Knowledge and risk perception (baseline, 2-years)</td>
</tr>
<tr>
<td></td>
<td>• Financial burden (6 months)</td>
</tr>
</tbody>
</table>
Inclusion criteria

- Age >40 at diagnosis
- All grade I and II DCIS (irrespective of necrosis/comedonecrosis)
- ADH/borderline DCIS
- Pathologic confirmation of grade I/II DCIS without invasion by 2 local pathologists
- ER and/or PR ≥ 10%; HER2-negative (0, 1+, or 2+ if testing performed)
- No evidence of breast disease on physical examination/breast imaging within 6 months of registration
COMET Study (AFT-25)
Comparison of Operative to Monitoring and Endocrine Therapy for Low-risk DCIS
Lynch T, Frank L, Collyar D, Basila D, Pinto D, Partridge A, Thompson A, Hwang S.

- Planned accrual goal 1200 randomized patients across 100 Alliance for Clinical Trials in Oncology sites
- Projected rate of 25% will withdraw or decline allocation (will continue to complete PRO surveys)
- Approximately 900 patients treated according to randomized arm, analyzed in an intent-to-treat analysis
- 2-year invasive cancer rate in GCC group assumed to be 0.10 with a non-inferiority margin of 0.05
- Sample size of n=446 per group will have 80% power to detect the specified non-inferiority margin
COMET Study (AFT-25)
Comparison of Operative to Monitoring and Endocrine Therapy for Low-risk DCIS
Lynch T, Frank L, Collyar D, Basila D, Pinto D, Partridge A, Thompson A, Hwang S.

- COMET study opened (July 2016)
- First site activated (February 2017)
- 75+ sites activated to date
- 100+ patients enrolled to date
- Comparable studies taking place in UK (LORIS) and Europe (LORD)
- Planned combined analysis of data
- Clinicaltrials.gov: NCT02926911
COMET Study (AFT-25)
Comparison of Operative to Monitoring and Endocrine Therapy for Low-risk DCIS
Lynch T, Frank L, Collyar D, Basila D, Pinto D, Partridge A, Thompson A, Hwang S.

The trial (COMET | AFT-25) is funded by an award (PCS-1505-30497) from the Patient-Centered Outcomes Research Institute.


To learn more about the COMET Study, please contact Thomas Lynch (Project Manager): thomas.lynch2@duke.edu. All statements in this poster are solely those of the authors and do not necessarily represent the views of PCORI, its Board of Governors or Methodology Committee.